Lorens S A, Van de Kar L D
Neuroendocrinology. 1987 Apr;45(4):305-10. doi: 10.1159/000124754.
The present study was designed to investigate the effect of distinct serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion. Low doses of the selective 5-HT1A agonists 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) (5.0-500.0 micrograms/kg, i.p.) and ipsapirone (TVX Q 7821; 0.5-2.5 mg/kg, i.p.), and of the 5-hydroxytryptamine (5-HT) agonist MK-212 (2.0 mg/kg, i.p.), did not elevate plasma renin activity (PRA) and concentration (PRC) 30 min postinjection. Administration of a higher dose of MK-212 (10.0 mg/kg, i.p.) and of higher doses of ipsapirone (5.0-10.0 mg/kg, i.p.), as well as the 5-HT releaser, fenfluramine (5.0 mg/kg, i.p.), resulted in large increases in PRA and PRC. The effects of MK-212 and fenfluramine on PRA and PRC were blocked by pretreatment with the selective 5-HT2 antagonist, LY53857, in a dose-dependent (0.3-1.0 mg/kg, i.p.) manner. LY53857 (1.0 mg/kg, i.p.) by itself did not affect PRA or PRC. LY53857, furthermore, unmasked a renin-suppressive effect of MK-212, since injection of MK-212 (10.0 mg/kg, i.p.) following LY53857 administration led to a reduction in PRA and PRC. MK-212 (2.0 and 10.0 mg/kg), the high doses of 8-OH-DPAT (500.0 micrograms/kg), ipsapirone (1.0-10.0 mg/kg), and fenfluramine (5.0 mg/kg) all produced an increase in plasma corticosterone levels. The effects of MK-212 and fenfluramine on corticosterone were not inhibited by pretreatment with LY53857. These data suggest that 5-HT1A receptors do not play a role in the regulation of renin secretion, whereas stimulation of 5-HT2 receptors enhances renin release.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在探讨不同的血清素(5-HT1A和5-HT2)激动剂和拮抗剂对肾素和皮质酮分泌的影响。低剂量的选择性5-HT1A激动剂8-羟基-2-(二-N-丙基氨基)四氢萘(8-OH-DPAT)(5.0 - 500.0微克/千克,腹腔注射)和ipsapirone(TVX Q 7821;0.5 - 2.5毫克/千克,腹腔注射),以及5-羟色胺(5-HT)激动剂MK-212(2.0毫克/千克,腹腔注射),在注射后30分钟未升高血浆肾素活性(PRA)和浓度(PRC)。给予较高剂量的MK-212(10.0毫克/千克,腹腔注射)、较高剂量的ipsapirone(5.0 - 10.0毫克/千克,腹腔注射)以及5-HT释放剂芬氟拉明(5.0毫克/千克,腹腔注射),导致PRA和PRC大幅升高。MK-212和芬氟拉明对PRA和PRC的作用可被选择性5-HT2拮抗剂LY53857(0.3 - 1.0毫克/千克,腹腔注射)预处理以剂量依赖性方式阻断。LY53857(1.0毫克/千克,腹腔注射)本身不影响PRA或PRC。此外,LY53857揭示了MK-212的肾素抑制作用,因为在给予LY53857后注射MK-212(10.0毫克/千克,腹腔注射)导致PRA和PRC降低。MK-212(2.0和10.0毫克/千克)、高剂量的8-OH-DPAT(500.0微克/千克)、ipsapirone(1.0 - 10.0毫克/千克)和芬氟拉明(5.0毫克/千克)均使血浆皮质酮水平升高。LY53857预处理未抑制MK-212和芬氟拉明对皮质酮的作用。这些数据表明,5-HT1A受体在肾素分泌调节中不起作用,而刺激5-HT2受体可增强肾素释放。(摘要截短至250字)